The Future of Somatostatin Receptor Ligands in Acromegaly

Currently, the first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical control in approximately 40% of patients and tumor shrinkage in over 60% of patients. Pasireotide, a second-generation SRL...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadelha, Monica R, Wildemberg, Luiz Eduardo, Kasuki, Leandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Mini-Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764337/
https://www.ncbi.nlm.nih.gov/pubmed/34618894
http://dx.doi.org/10.1210/clinem/dgab726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764337/
https://www.ncbi.nlm.nih.gov/pubmed/34618894
http://dx.doi.org/10.1210/clinem/dgab726

Ejemplares similares